BFM
RVNC

Boothbay Fund Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Boothbay Fund Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,477
Closed -$41K – 1904
2024
Q4 		$41K Buy
+13,477
New +$58.7K ﹤0.01% 1382
2022
Q4 		– Sell
-20,619
Closed -$557K – 2522
2022
Q3 		$557K Buy
+20,619
New +$418K 0.01% 1172
2021
Q4 		– Sell
-8,355
Closed -$233K – 2297
2021
Q3 		$233K Sell
8,355
-873
-9% -$24.9K 0.01% 1482
2021
Q2 		$274K Buy
+9,228
New +$266K 0.01% 1340
2020
Q4 		– Sell
-15,718
Closed -$395K – 1462
2020
Q3 		$395K Sell
15,718
-3,462
-18% -$90.8K 0.02% 729
2020
Q2 		$468K Sell
19,180
-4,720
-20% -$93.2K 0.03% 598
2020
Q1 		$354K Sell
23,900
-19,300
-45% -$399K 0.03% 528
2019
Q4 		$701K Buy
+43,200
New +$670K 0.06% 398
2018
Q2 		– Sell
-10,878
Closed -$335K – 931
2018
Q1 		$335K Buy
+10,878
New +$350K 0.04% 431

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Boothbay Fund Management's RVNC Position: Q1 2025 in Review

Boothbay Fund Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 13,477 shares — an estimated $41K sold.

Boothbay Fund Management first reported a position in RVNC in Q1 2018 and held it in 9 quarters. The position peaked at $701K in Q4 2019. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Boothbay Fund Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 13,477 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $41K.
  • Boothbay Fund Management first reported a position in Revance Therapeutics, Inc. in Q1 2018 and held it in 9 quarters.
  • Boothbay Fund Management's Revance Therapeutics, Inc. position peaked at $701K in Q4 2019.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Boothbay Fund Management's 13F filing for Q1 2025, filed 15 May 2025.